N. Yamagata

A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin

Kamalesh K. Sankhala, Akira Mita, R. Adinin et al. · Journal of Clinical Oncology · 2009 · 81 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Abstract C36: MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro-esophageal adenocarcinoma, with pharmacokinetics

Neil Senzer, Kazuhiko Matsuno, N. Yamagata et al. · Molecular Cancer Therapeutics · 2009 · 40 citations

Pharmacy, Oncology, Pharmacology +15

Changes in Simple and Complex Behaviors Following Kindled Seizures in Rats: Opioid and Nonopioid Mediation

S Caldecott-Hazard, N. Yamagata, Jenny Hedlund et al. · Epilepsia · 1983 · 20 citations

Life Sciences, Neuroscience, Pharmacology +14

Clinical phase 1b study results for safety, pharmacokinetics and efficacy of ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 SIRNA for the treatment of Japanese patients with advanced liver fibrosis

Naoya Sakamoto, K Ogawa, Goki Suda et al. · Journal of Hepatology · 2018 · 17 citations

Pharmacy, Pharmaceutics, Pharmacology +14

[Lung injury associated with bucillamine therapy].

Masao Negishi, Shuji Kaga, Toshihiro Kasama et al. · PubMed · 1992 · 15 citations

Medicine, Immunology, Internal Medicine +12